21st Oct 2020 20:31
PureTech Health PLC - biotherapeutics company - Says its founded entity Akili reports new trial data for Digital Therapeutic EndeavorRx in paediatric attention deficit hyperactivity disorder. Study shows two-thirds of parents reported real-world improvements in child's ADHD-related impairments following two months of treatment, both when used alone and alongside stimulants. Improvements in attention during treatment were associated with improvements in maths and reading performance. Data across four clinical trials consistently demonstrate over one-third of children with ADHD no longer showed attention impairment on at least one measure of objective attention.
Current stock price: 243.00 pence
Year-to-date change: down 24%
By Arvind Bhunjun; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
PureTech